Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Aditxt Inc.

Healthcare US ADTX

0.0189USD
-0.01(34.60%)

Last update at 2026-06-10T18:57:00Z

Day Range

0.020.02
LowHigh

52 Week Range

0.302495.04
LowHigh

Fundamentals

  • Previous Close 0.03
  • Market Cap0.28M
  • Volume145023758
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-19.30145M
  • Revenue TTM0.00319M
  • Revenue Per Share TTM0.09
  • Gross Profit TTM 0.00027M
  • Diluted EPS TTM-8190.53

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -42787.04300M -35.02000M -32.39045M -27.64988M -46.37136M
Minority interest 1.07M 0.57M 0.00961M - -
Net income -43101.45100M -34.44600M -32.38084M -28.19381M -48.30993M
Selling general administrative 15974.86M 16.29M 18.61M 15.99M 22.08M
Selling and marketing expenses 402.00M 0.20M 0.27M 1.85M 0.33M
Gross profit 0.27M -0.49300M -0.11166M 0.17M 0.03M
Reconciled depreciation 0.27M 0.62M 0.54M 0.54M 0.48M
Ebit -19.57072M -27.65625M -26.00055M -24.93616M -27.43493M
Ebitda -19.29812M -27.03900M -25.45796M -24.28387M -26.95559M
Depreciation and amortization 0.27M 0.62M 0.54M 0.65M 0.48M
Non operating income net other - - - - -
Operating income -19570.72400M -27.86400M -26.06243M -24.93616M -27.43493M
Other operating expenses 19573.92M 28.00M 26.71M 25.87M 27.54M
Interest expense 2.39M 7.36M 6.39M 2.29M 1.94M
Tax provision 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Interest income 0.20M 0.00145M 0.01M 0.06M 0.00310M
Net interest income -2.18767M -7.36219M -6.37973M -2.22874M -1.93547M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 314.41M 5333.44M 0.31M 0.54M 1.94M
Total revenue 3.19M 0.13M 0.65M 0.93M 0.11M
Total operating expenses 19570.99M 27.37M 25.95M 25.10M 27.46M
Cost of revenue 2.93M 0.63M 0.76M 0.77M 0.08M
Total other income expense net -23216.31900M -7.15600M -6.32802M -2.71372M -18.93644M
Discontinued operations - - - - -
Net income from continuing ops -42.78704M -35.02006M -32.39045M -27.64988M -46.37136M
Net income applicable to common shares - - - -27.61220M -46.37136M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 16.52M 32.14M 44.58M 10.74M 16.66M
Intangible assets 2.78M 0.00611M 0.00944M 0.11M 0.21M
Earning assets - - - - -
Other current assets -3200.55127M -832.19459M 0.22M 0.50M 0.46M
Total liab 12.56M 23.86M 28.53M 5.53M 6.48M
Total stockholder equity 5.61M 8.29M 16.06M 5.21M 10.18M
Deferred long term liab - - - 0.05M -
Other current liab -2659.55248M 6.73M 0.16M 2.15M 1.76M
Common stock 0.00041M 0.00013M 0.00132M 0.00431M 0.04M
Capital stock 0.00044M 8.37M 0.00134M 0.00431M 0.04M
Retained earnings -209.80877M -168.09457M -127.74107M -95.04036M -67.35281M
Other liab - - - - -
Good will - 6.10M - - -
Other assets - -1998.23903M - 0.41M 0.67M
Cash 3198.60M 0.83M 0.10M 2.77M 7.87M
Cash and equivalents - - - - -
Total current liabilities 12.22M 23.41M 25.89M 3.64M 3.61M
Current deferred revenue - - - - -
Net debt -192.07100M 6.09M 18.12M 0.61M -3.15053M
Short term debt 2664.43M 6.48M 17.18M 1.50M 1.85M
Short long term debt 1.86M 5.80M 16.18M 0.41M 0.70M
Short long term debt total 3006.53M 6.92M 18.22M 3.38M 4.72M
Other stockholder equity 214.16M 168.59M 143.80M 100.24M 77.49M
Property plant equipment - - - 5.48M 6.36M
Total current assets 3.82M 2.00M 6.91M 4.74M 9.42M
Long term investments 6.65M 27.28M 22.28M - -
Net tangible assets - - - 5.10M 9.97M
Short term investments - 832.20M - - -
Net receivables 0.00000M 1.15M 5.85M 0.53M 0.59M
Long term debt - - - - 0.11M
Inventory 5.77M 0.01M 0.75M 0.95M 0.49M
Accounts payable 7.34M 10.19M 8.55M 1.96M 1.58M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 1.25M - -0.00002M - -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other -2085.39587M -0.31019M 0.11M 0.41M 0.67M
Deferred long term asset charges - - - - -
Non current assets total 12.70M 30.14M 37.67M 5.99M 7.25M
Capital lease obligations 1.15M 1.12M 2.04M 2.97M 3.91M
Long term debt total - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 0.00000M -5.00000M -0.01441M -0.24192M -16.30529M
Change to liabilities - - - 0.41M 1.33M
Total cashflows from investing activities -2438.74300M -5.00000M -0.01441M -0.24192M -16.30529M
Net borrowings -5.53786M -1.39879M 5.75M -0.81238M 2.89M
Total cash from financing activities 30492.67M 22.50M 16.55M 17.53M 35.95M
Change to operating activities - - - -0.41423M -0.61941M
Net income -42787.04300M -34.44600M -32.38084M -27.64988M -46.37136M
Change in cash 2365.57M 0.74M -2.67154M -5.10342M -2.62877M
Begin period cash flow 833.03M 0.10M 2.77M 7.87M 10.50M
End period cash flow 3198.60M 0.83M 0.10M 2.77M 7.87M
Total cash from operating activities -25688.35900M -16.76212M -18.57681M -22.39201M -22.27814M
Issuance of capital stock 44.13M 21.17M 11.06M 17.25M 29.87M
Depreciation 272.60M 0.62M 0.54M 0.54M 0.48M
Other cashflows from investing activities -2422.57500M -5.00000M - 0.13M -15.28954M
Dividends paid - - - - -
Change to inventory 0.00547M 0.73M 0.20M -0.45540M -0.49470M
Change to account receivables 0.04M 0.36M 0.12M -0.03677M -0.08984M
Sale purchase of stock -9.20644M -2.85187M -0.00100M -0.02000M -
Other cashflows from financing activities 30463.29M 2.73M 0.63M 4.00M 7.00M
Change to netincome - - - 3.68M 21.64M
Capital expenditures 13.74M 0.00000M 0.01M 0.37M 1.02M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -6.17188M 7.09M 9.10M -0.49344M 0.13M
Stock based compensation 473.31M 6.75M 1.40M 3.13M 4.64M
Other non cash items 16358.94M 3.23M 2.76M 2.08M 1.85M
Free cash flow -25702.10200M -16.76212M -18.59122M -22.75908M -23.29390M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
ADTX
Aditxt Inc. 		-0.01 34.60% 0.02 - 0.35 87.19 0.06 38.12 0.02
NVO
Novo Nordisk A/S		 0.94 2.22% 43.12 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 1.70 4.09% 43.30 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -9.785 2.20% 435.99 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 -11.82 1.92% 604.36 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Aditxt, Inc., a commercial-stage company, discovers and develops products in the areas of immune health, precision health, population health, women's health, and neurologic health. The company develops AditxtScore that enable individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its tissues. It also develops ADI-100 for skin grafting, psoriasis, type 1 diabetes, and multiple sclerosis. Aditxt, Inc. has a license agreement with Loma Linda University and Leland Stanford Junior University. The company was formerly known as ADiTx Therapeutics, Inc. and changed its name to Aditxt, Inc. in July 2021. Aditxt, Inc. was incorporated in 2017 and is headquartered in Mountain View, California.

Aditxt Inc.

2569 Wyandotte Street, Mountain View, CA, United States, 94043

Key Executives

Name Title Year Born
Mr. Amro A. Albanna Co-Founder, Chairman & CEO 1970
Ms. Corinne D. Pankovcin CPA, CPA, M.B.A. Pres 1966
Dr. Shahrokh Shabahang D.D.S., M.S., Ph.D. Co-Founder, Chief Innovation Officer, Sec. & Director 1963
Mr. Thomas J. Farley CPA Chief Financial Officer 1973
Ms. Rowena Albanna Chief Operating Officer 1966
Mr. Matthew M. Shatzkes Chief Legal Officer & Gen. Counsel NA
Ms. Jennifer Lee Director of HR NA
Dr. Dolly B. Tyan Ph.D. Sr. VP of Clinical Devel. ? Transplantation NA
Mr. Ge Chen M.D., M.S. Sr. VP of Preclinical Research & Discovery NA
Dr. Shahrokh Shabahang D.D.S., M.S., Ph.D. Co-Founder, Chief Innovation Officer, Secretary & Director 1963

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions